Stockscreener 앱 받기
2.41
3.43%
0.08
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute - TipRanks
Assenagon Asset Management S.A. Increases Stock Holdings in Premier, Inc. (NASDAQ:PINC) - Defense World
Can this 10.8% yield from a FTSE 250 share last? - Yahoo Finance UK
CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals Launches Pivotal Phase 1/2 Trial for Novel ITP Treatment CID-103 - StockTitan
Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld Online
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
Is a stock market crash coming? And what should I do now? - Yahoo Finance UK
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
Pre-market Movers: SXTC, STIM, BIOA, UPC... - RTTNews
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan
CASI Pharmaceuticals Inc (CASI) Quarterly 10-Q Report - Quartzy
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - GuruFocus.com
(CASI) Proactive Strategies - Stock Traders Daily
CASI Pharmaceuticals gets China nod for ITP treatment trial - Investing.com
CASICASI Pharmaceuticals, Inc. Ordinary Shares Latest Stock News & Market Updates - StockTitan
CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
CASI Pharmaceuticals gets China nod for ITP treatment trial By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update - MarketBeat
Objective long/short (CASI) Report - Stock Traders Daily
Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Defense World
(CASI) Trading Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.67 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Yahoo Finance
0.40%
0.84%
자본화:
|
볼륨(24시간):